Skip to main content
. Author manuscript; available in PMC: 2012 Apr 14.
Published in final edited form as: ACS Med Chem Lett. 2011 Apr 14;2(4):313–315. doi: 10.1021/ml1003074

Table 1.

Cytotoxicity evaluation of (−)-(R)- and (+)-(S)-boehmeriasin A in comparison to paclitaxel.

Compound IC50 (nM)

COLO-205 MCF-7 NCI-ADR-RES
paclitaxela 3.31 1.62 >6400
(−)-(R)-1·HClb 4.18 43.4 36.7
(+)-(S)-1·HCla 103 92.7 434

COLO-205 = human colorectal adenocarcinoma (GI50 = 0.80 nM reported for (-)-1, see ref. 1); MCF-7 = human breast carcinoma (GI50 = 13 nM reported for (-)-1, see ref. 1); NCI-ADR-RES = drug-resistant human ovarian adenocarcinoma;

a

average of six assays each;

b

average of three assays each.